Thrombotic thrombocytopenic purpura (TTP) related to systemic lupus erythematosus may not cause worse outcomes compared with primary immune-mediated TTP.
TTP is a rare disease that clinicians may not often treat; however, it is important to be aware of new developments for the treatment of this patient population.
In patients hospitalized with COVID-19, thrombi in segmental pulmonary arteries are common and are located in opacitated lung segments, which may suggest local clot formation.
A position paper recently published by the National Pulmonary Embolism Response Team outlines an approach for diagnosing and treating pulmonary embolism in patients with COVID-19.
Investigators assess underlying mechanisms and relevant biomarkers of morbidity and mortality due to coagulopathy in patients with severe COVID-19 infection.
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
Researchers studied the effect of certain biomarkers on long-term adverse cardiovascular outcomes in patients with coronary morbidities undergoing PCI.
As thromboembolism is a common side effect of ALL treatment, investigators assessed whether its occurrence in ALL and in the general adult population have a shared genetic basis.
As PKD directly affects the catalysis of substrates and products involved in the production of ATP, the glycolytic pathway is compromised, thus leading to several cellular defects.
A prospective, single-center study aimed to determine the prevalence of DVT after TKA among patients with hemophilia A and found that contrast-enhanced CT led to better detection compared with ultrasound.
In a number of COVID-19 autopsies, thrombosis of multiple organs was a prominent feature, regardless of timing of disease course and anticoagulation status.
The British Society of Haematology released updates to 2 previous guidelines to help clinical laboratories with assays for coagulant diagnostic services.
Anagrelide, a platelet-lowering agent with US FDA approval and EMA licensing for the treatment of patients with ET, is associated with prolonged response to initial therapy.
It may be important to sequence ETV6in patients with inherited thrombocytopenia or malignancy and to schedule regular follow-ups to check for secondary cancers.
Replacing DOACs with alternative parenteral antithrombotic strategies may help to prevent bleeding complications in patients with SARS-CoV-2 infection.
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
Investigators compared the use of DOACs with traditional therapies in patients with acute VTE who were either discharged directly from the ED or hospitalized.
Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.
Compared with controls, the experimental mouse model group was less susceptible to arterial thrombosis in settings using ferric chloride and laser injury–induced thrombosis.
